Flavia Jacobs

MD | Medical Oncologist at @humanitasmilano 🇮🇹 Previous Research Fellow at @julesbordet 🇧🇪 | Interest in #BreastCancer

[Flavia Jacobs @FlaviaJacobs_]

@HUNIMED @HumanitasMilano is present at #AIOM24 with our posters. Great professors and colleagues 💫💛

[Flavia Jacobs @FlaviaJacobs_]

Just attended the #ESMO advanced course on Antibody-Drug Conjugates #ADC in Zurich!🇨🇭

Excellent discussion on development, therapeutic application, future trials and management of toxicities of this innovative class of drugs 💊

Thank you @myESMO for this enriching experience!

[Elisa Agostinetto @ElisaAgostinett]

At #ESMO24 @E_de_Azambuja talks about cardiac immune-related adverse events❤️‍🩹
Myocarditis has low incidence but high mortality risk⚠️
Up to 30% of myocarditis can be associated with other irAEs (myositis, myasthenia)‼️ Remind to rule out the “overlap syndrome”

@OncoAlert

[Guilherme Nader Marta @GuiNaderMarta]

Neo-CheckRay presented by @AlexDeCaluwe

Ph2 II trial in early LumB BC, exploring NACT + SBRT + IO (anti-PD-L1, anti-CD73)

The addition of IO to NACT+SBRT numerically improved RCB0/1 rates (38% vs 51%, P = 0.2)

Incredibly proud to be part of this effort!

@OncoAlert

[Véronique Debien @VeroniqueDebien]

The mentorship is a KEY 🔑🚀 @E_de_Azambuja

[Elisa Agostinetto @ElisaAgostinett]

At #ESMO24 @nlinmd presents data on T-DXd in Destiny-Breast12

T-DXd showed substantial overall and intracranial clinical activity in pts with HER2+ mBC 🧠

Median PFS 17.3 mos and CNS ORR 72% in pts with baseline brain mets

@OncoAlert

[Flavia Jacobs @FlaviaJacobs_]

Check out our last review on activity biomarker and toxicity of PI3K/Akt targeted agents led by @marisirico published in @CHematology ⬇️⬇️

[Guilherme Nader Marta @GuiNaderMarta]

PI3K/Akt-targeted agents entered clinical practice & may soon bring precision oncology to 1st line of Tx for ER+ breast cancer

Out in @CHematology our review on the activity, biomarkers & toxicities w/ these agents & next steps in the field

https://t.co/gvVYcT0wbn

@OncoAlert

[Marta Perachino @MartaPerachino]

Most awaited results @ #ASCO24 on the topic of breast cancer
⏯️ stay tuned for @OncoAlert selection on other topics 🛫🛫

[Elisa Agostinetto @ElisaAgostinett]

#ESMOBreast24 is getting to the end. Another fulfilling experience - very proud to have been awarded with a @myESMO Merit travel grant for our work🙏🏻
A big❤️to all colleagues and friends that made it possible and help improve #breastcancer care everyday
@OncoAlert @JulesBordet

[Diogo Martins Branco @DMBranco]

🗞 hot off the press @myESMO #RealWorldData & #DigitalOncology

📢 #RWE use for pre-authorisation efficacy evaluation reported in 21% of targeted therapy approvals for solid malignancies
📈 from 2018 to 2022
✅️ 75% supportive

📍Data revisited focusing on #bcsm #ESMOBreast24

[Flavia Jacobs @FlaviaJacobs_]

✔️we develop a #ML tool to predict #RSClin to refine DR risk and CT benefit for HR+HER2- #earlyBC
✔️our tool can accurately reproduce RSClin
✔️free web based link to access the tool ➡️ https://t.co/ORlPwYWnh5
✔️this tool may support treatment decision for HR+ eBC
#ESMOBreast24

[Flavia Jacobs @FlaviaJacobs_]

Determining when to escalate or descalate treatment in HER2+ breast cancer requires additional clinical trials.

@E_de_Azambuja @myESMO #ESMOBreast24

[Paolo Tarantino @PTarantinoMD]

Less than 48h to #ESMOBreast24: time for the #top10 abstracts. Highly awaited readout from IMp132, safety update of important ph 3 trials (TB01, NATALEE), intriguing biomarker analyses from large datasets (HER2DX, monarchE) and much more. Promises to be a terrific congress! #bcsm

[Flavia Jacobs @FlaviaJacobs_]

At the #AI for #Oncology congress, we presented our research on #SD generated through #GANs to augment a dataset of HR+/HER2- eBC. SD mirrored the characteristics of the real cohort while ensuring privacy protection.
This support multimodal data integration with AI in oncology

[JAMA @JAMA_current]

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. https://t.co/IvPjnLX3EB

[Paolo Tarantino @PTarantinoMD]

Does HER2-low expression impact the incidence of CNS disease from breast cancer?

Large analysis (n≃20.000) from the ESME database shows similar incidence and outcomes for brain mets & LMD between HER2-low vs HER2-0 MBC, but higher incidence in HER2+.

Published in @ESMO_Open 🔥

[Yakup Ergün @dr_yakupergun]

Ribociclib plus Endocrine Therapy in Early Breast Cancer : NATALEE

3y-iDFS: 90.4% vs 87.1% (HR:0.75)

https://t.co/tdzIF8ctHs

[Elisa Agostinetto @ElisaAgostinett]

Now out in #ClinicalBreastCancer our subanalysis of the #CLEOPATRA study led by @VeroniqueDebien showing that patients with radiological complete response at 1️⃣st disease re-evaluation have significantly ⬆️ survival

@OncoAlert

https://t.co/9e4RaYBEVU

[Flavia Jacobs @FlaviaJacobs_]

In this analysis led by @VeroniqueDebien, MD, MSc, findings from the CLEOPATRA trial suggest that radiological complete response at first imaging re-evaluation in HER2-positive metastatic breast cancer patients predicts longer PFS and OS.

[Guilherme Nader Marta @GuiNaderMarta]

Many pts w/ HER2+ BC have long-term response to trastuzumab-pertuzumab ➡️ >16% without progression at 8y in #CLEOPATRA

In this analysis led by @VeroniqueDebien we show that complete response at first imaging re-evaluation correlates with longer PFS & OS

@OncoAlert #bcsm

[merve @mervenoyann]

MLX is in AI conferences now @r_musmeci @awnihannun
Also MLX-Image is on @huggingface Hub 🤗
It's very similar to PyTorch if you want to get started: https://t.co/sARc59YYmV